Answers are grounded in this paper and cite their sources.
Cost-effectiveness analyses assess aztreonam-avibactam value in Spain, indicating important implications for policy.
returns on investment for new antimicrobials, [3] this has led to under-investment in antimicrobial research and development.Quantifying the additional value of antimicrobials is essential for informing policy decisions, such as incentives to support the research and development of new antimicrobials.Two cost-effectiveness analyses of aztreonam-avibactam (ATM-AVI) in Spain [4,5] have been published and provide the opportunity to compare how modelling choices influence the valuation of antimicrobials.Both models COMMENTARYThe challenge of determining the full value of antimicrobials is a persistent problem while antimicrobial resistance (AMR) continues to rise [1].Traditional health technology assessment (HTA) frameworks capture patient-level benefits but commonly overlook population-level benefits, such as slowed resistance development and reduced transmission [2].
No takes yet. Share an insight, caveat, or question.
Luque et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: